<DOC>
	<DOCNO>NCT02141100</DOCNO>
	<brief_summary>The purpose phase 1-2 study explore applicability supplement standard methotrexate/6-mercaptopurine ( MTX/6MP ) maintenance therapy child non-Hodgkin lymphoma 6-thioguanine ( 6TG ) . The investigator hypothesize addition 6TG 6MP-based maintenance therapy patient high TPMT activity mimic favourable thiopurine metabolism patient low TPMT activity ultimately reduce relapse rate .</brief_summary>
	<brief_title>Study 6-Thioguanine Combination With 6-Mercaptopurine During Maintenance Therapy Childhood Lymphoma</brief_title>
	<detailed_description>MTX/6MP maintenance therapy challenge treatment relate liver toxicity , failure achieve target treatment parameter patient , lack direct parameter monitor treatment efficacy even intensity . Patients low activity thiopurine methyltransferase ( TPMT ) , enzyme involved metabolism 6MP , low level liver toxic metabolite ( MeMPs ) , high level major active metabolite ( TGNs ) , reduce relapse rate . Most patient ( 90 % ) high TPMT activity . Nearly patient high TPMT activity high MeMP level experience elevate liver enzymes . Increasing 6MP dose patient high TPMT activity , intensify therapy , mainly lead increase MeMP level . A novel approach compensate adverse thiopurine metabolism majority patient warrant .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Confirmed histomorphological cytomorphological diagnosis NHL ALL . Meets one following : 1 . Patient NHL treat EUROLB 02 protocol least 3.5 month 6MP/MTX maintenance therapy remain 2 . Patient ALL NHL achieve target WBC ( patient WBC &gt; 3.0 x10^9/L ) and/or experience elevate liver enzymes ( ALAT &gt; UNL ) attribute simultaneous high EryMeMP level standard MTX/6MP maintenance therapy . TPMT wildtype genotype TPMT high activity phenotype ( TPMT activity 14 IU/mL maintenance therapy TPMT 8 IU/mL measure erythrocyte ) . Bilirubin &lt; 35 micromol/L , factor 2710 &gt; 0.5 INR &lt; 1.5 normal hepatic blood flow ( verified ultrasound ) within 1 week prior inclusion . WBC &gt; 1.5 x10^9/L , ANC &gt; 0.5 x10^9/L TBC &gt; 50 x10^9/L within 1 week prior inclusion . Pubertal female , Tanner stage B3/PH3 high , must present negative pregnancy test . Sexually active female must use accepted safe contraception ( OCPs , IUD , transdermal hormonal patch , vaginal hormonal ring subdermal hormonal implant ) therapy month completion therapy . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule . Oral write informed consent participate provide parent ( appropriate patient ) accord ICH/GCP guideline Helsinki II Declaration . Patients acute lymphoblastic lymphoma ( 017.9 yr ) achieve target WBC ( patient WBC &gt; 3.0 x10^9/L ) and/or experience elevate liver enzymes ( ALAT &gt; UNL ) attribute simultaneous high EryMeMP level standard MTX/6MP maintenance therapy . Any clinical suspicion relapse disease progression routine image laboratory result . Previous venoocclusive disease ( VOD ) . Allergy towards ingredient three medicinal product use study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>thioguanine</keyword>
	<keyword>mercaptopurine</keyword>
	<keyword>methotrexate</keyword>
</DOC>